Top Markets
#1 EXOD EXOD +22.08%
#2 Status Status +18.25%
#3 Ontology Gas Ontology Gas +14.98%
#4 Fake World Assets Fake World Assets +9.05%
#5 Derive Derive +8.72%
#6 aelf aelf +8.29%
#7 Anvil Anvil +5.72%
#8 Tornado Cash Tornado Cash +5.44%
#9 The Black Bull The Black Bull +5.21%
#10 B3 (Base) B3 (Base) +5.04%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
Classifica tra le azioni #25718
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Prezzo delle azioni
$1.45
Ultima sincronizzazione: 2026-08-19
Capitalizzazione di mercato
$46.94M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-18.08%
Paese
US
Scambia Vicapsys Life Sciences, Inc. (VICP)

Categoria

Healthcare
Rapporto P/B per Vicapsys Life Sciences, Inc. (VICP)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Vicapsys Life Sciences, Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Vicapsys Life Sciences, Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US